Skip to main content
SpringerLink
Log in

Interstitielle Lungenerkrankung (ILD) – wann und wie behandeln?

Interstitial Lung Disease (ILD)—when and how to treat

  • So behandle ich ...
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Krause A, Rubbert-Roth A (2019) Lungenbeteiligung bei rheumatoider Arthritis. Z Rheumatol 78:228–235

    Article  CAS  Google Scholar 

  2. Demoruelle MK, Mittoo S, Solomon JJ (2016) Connective tissue disease-related interstitial lung disease. Best Pract Res Clin Rheumatol 30:39–52

    Article  Google Scholar 

  3. Hyldgaard C, Hilberg O, Pedersen AB et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700–1706

    Article  Google Scholar 

  4. Correla CS, Briones MR, Guo R et al (2019) Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clin Rheumatol 38:1201–1206

    Article  Google Scholar 

  5. Sparks JA, He X, Huang J et al (2019) Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis–associated interstitial lung disease: a prospective cohort study. Arthritis Rheum 71:1472–1482

    Article  CAS  Google Scholar 

  6. Tsuchiya Y, Takayanagi N, Sugiura H et al (2011) Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37:1411e7

    Article  Google Scholar 

  7. Fernandez-Diaz C, Loricera J, Castaneda S et al (2018) Abatacept in Patients With Rheumatoid Arthritis and Interstitial Lung Disease: A National Multicenter Study of 63 Patients. Semin Arthritis Rheum 48:22–27

    Article  CAS  Google Scholar 

  8. Duarte AC, Porter JC, Leandro MJ (2019) The lung in a cohort of rheumatoid arthritis patients—an overview of different types of involvement and treatment. Baillieres Clin Rheumatol 58:2031–2038

    Google Scholar 

  9. Fragoulis GE, Conway R, Nikiphorou E (2019) Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature. Baillieres Clin Rheumatol 58:1900–1906

    CAS  Google Scholar 

  10. Fischer A, Brown KK, Du Bois RM et al (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 40:640–646

    Article  CAS  Google Scholar 

  11. Manfredi A, Cassone G, Furini F et al (2019) Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study. Intern Med J. https://doi.org/10.1111/imj.14670

    Article  Google Scholar 

  12. Flaherty KR, Wells AU, Cottin V et al (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 381:1718–1727

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kommission Pharmakotherapie der DGRh e. V., Rheumatologisches Praxiszentrum, St. Bonifatius-Str. 5, 81541, München, Deutschland

    K. Krüger

Authors
  1. K. Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Krüger.

Ethics declarations

Interessenkonflikt

K. Krüger gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

J. Holle, Neumünster

F. Moosig, Neumünster

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Krüger, K. Interstitielle Lungenerkrankung (ILD) – wann und wie behandeln?. Z Rheumatol 79, 780–781 (2020). https://doi.org/10.1007/s00393-020-00829-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-020-00829-9

Search

Navigation